Business Wire

57% of patients treated with IMFINZI were alive at three years in ADRIATIC Phase III trial

WILMINGTON, Del.--(BUSINESS WIRE)-- Positive results from the ADRIATIC Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) ​demonstrated statistically significant and clinically meaningful improvements in the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) compared to placebo for patients with limited-stage small cell lung... (continue reading...)

• DESTINY-Breast06 results show Daiichi Sankyo and AstraZeneca’s ENHERTU is the first HER2 directed medicine and antibody drug conjugate to demonstrate clinically meaningful benefit for patients in this setting
• Additionally, data from DESTINY-Breast03 and DESTINY-Breast07 trials in HER2 positive metastatic breast cancer reinforce ENHERTU as standard of care in second-line setting and highlight potential in first-line setting

TOKYO & BASKING RIDGE,... (continue reading...)

DESTINY-Breast06 results show AstraZeneca and Daiichi Sankyo’s ENHERTU is the first HER2-directed medicine and ADC to demonstrate clinically meaningful benefit for patients in this setting

Additionally, data from DESTINY-Breast03 and DESTINY-Breast07 trials in HER2-positive metastatic breast cancer reinforce ENHERTU as standard of care in 2nd-line setting and highlight potential in 1st-line setting

WILMINGTON, Del.--(BUSINESS WIRE)-- Detailed positive results... (continue reading...)

Combination of AI-enabled clinical trial matching, genetic testing, symptom management, psychosocial, and lifestyle support addresses physical and mental health gaps patients experience in seeking and accessing treatments while accelerating access to these critical resources.

CHICAGO--(BUSINESS WIRE)-- ASCO Annual Meeting – Massive Bio, a renowned leader in AI-driven oncology solutions and Mika Health, the premier oncology digital therapeutic platform, today... (continue reading...)

– In Cohort B of the ARC-9 mCRC Study, Etrumadenant Plus Zimberelimab, FOLFOX Chemotherapy and Bevacizumab Significantly Reduced the Risk of Death by 63% and Risk of Disease Progression by 73% Compared to Regorafenib in a Phase 1b/2 Trial –

– Results will be Presented Today During an Oral Session at the ASCO Annual Meeting –

FOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: ... (continue reading...)